central

Measles outbreak in central Ohio affects more than 50 children, due to 'lack of vaccination' |  CNN

Measles outbreak in central Ohio affects more than 50 children, due to ‘lack of vaccination’ | CNN

CNN — A measles outbreak in central Ohio is growing, sickening more than 50 children, many of whom require hospitalization, according to data updated Tuesday by Columbus Public Health. None of the children had been fully vaccinated against measles. Since the outbreak began in November, at least 58 measles cases have been identified in Columbus …

Measles outbreak in central Ohio affects more than 50 children, due to ‘lack of vaccination’ | CNN Read More »

Measles outbreak in central Ohio affects more than 50 children, due to 'lack of vaccination' |  CNN

Measles outbreak in central Ohio affects more than 50 children, due to ‘lack of vaccination’ | CNN

CNN — A measles outbreak in central Ohio is growing, sickening more than 50 children, many of whom require hospitalization, according to data updated Tuesday by Columbus Public Health. None of the children had been fully vaccinated against measles. Since the outbreak began in November, at least 58 measles cases have been identified in Columbus …

Measles outbreak in central Ohio affects more than 50 children, due to ‘lack of vaccination’ | CNN Read More »

Praxis Precision Medicines to Advance Phase 2 PRAX-562 Study in Pediatric Patients with Developmental Encephalopathies and Epilepsy |  MarketScreener

Praxis Precision Medicines to Advance Phase 2 PRAX-562 Study in Pediatric Patients with Developmental Encephalopathies and Epilepsy | MarketScreener

BOSTON, November 28, 2022 (GLOBE NEWSWIRE) — Praxis Precision MedicinesInc. (NASDAQ: PRACTICE), a clinical-stage biopharmaceutical company applying genetic insights to develop therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced plans to launch the PRACTICE-562 EMBOLD Phase 2 study for the treatment of pediatric patients with developmental and epileptic encephalopathies …

Praxis Precision Medicines to Advance Phase 2 PRAX-562 Study in Pediatric Patients with Developmental Encephalopathies and Epilepsy | MarketScreener Read More »